|
1
|
Zduriencikova M, Gronesova P, Cholujova D
and Sedlak J: Potential biomarkers of exosomal cargo in endocrine
signaling. Endocr Regul. 49:141–150. 2015. View Article : Google Scholar
|
|
2
|
Paracha N, Thuresson PO, Moreno SG and
MacGilchrist KS: Health state utility values in locally advanced
and metastatic breast cancer by treatment line: A systematic
review. Expert Rev Pharmacoecon Outcomes Res. 16:549–559. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Osborne C, Wilson P and Tripathy D:
Oncogenes and tumor suppressor genes in breast cancer: Potential
diagnostic and therapeutic applications. Oncologist. 9:361–377.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Logan GJ, Dabbs DJ, Lucas PC, Jankowitz
RC, Brown DD, Clark BZ, Oesterreich S and McAuliffe PF: Molecular
drivers of lobular carcinoma in situ. Breast Cancer Res. 17:762015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Panno ML, Naimo GD, Spina E, Andò S and
Mauro L: Different molecular signaling sustaining adiponectin
action in breast cancer. Curr Opin Pharmacol. 31:1–7. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun W, Yang Y, Xu C and Guo J: Regulatory
mechanisms of long noncoding RNAs on gene expression in cancers.
Cancer Genet. 216-217:105–110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Baldinu P, Cossu A, Manca A, Satta MP,
Sini MC, Palomba G, Dessole S, Cherchi P, Mara L, Tanda F, et al:
CASC2a gene is down-regulated in endometrial cancer. Anticancer
Res. 27:235–243. 2007.PubMed/NCBI
|
|
8
|
Palmieri G, Paliogiannis P, Sini MC, Manca
A, Palomba G, Doneddu V, Tanda F, Pascale MR and Cossu A: Long
non-coding RNA CASC2 in human cancer. Crit Rev Oncol Hematol.
111:31–38. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li P, Xue WJ, Feng Y and Mao QS: Long
non-coding RNA CASC2 suppresses the proliferation of gastric cancer
cells by regulating the MAPK signaling pathway. Am J Transl Res.
8:3522–3529. 2016.PubMed/NCBI
|
|
10
|
Gan Y, Han N, He X, Yu J, Zhang M, Zhou Y,
Liang H, Deng J, Zheng Y, Ge W, et al: Long non-coding RNA CASC2
regulates cell biological behaviour through the MAPK signalling
pathway in hepatocellular carcinoma. Tumour Biol.
39:10104283177062292017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pei Z, Du X, Song Y, Fan L, Li F, Gao Y,
Wu R, Chen Y, Li W, Zhou H, et al: Down-regulation of lncRNA CASC2
promotes cell proliferation and metastasis of bladder cancer by
activation of the Wnt/β-catenin signaling pathway. Oncotarget.
8:18145–18153. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang R, Li Y, Zhu G, Tian B, Zeng W, Yang
Y and Li Z: Long noncoding RNA CASC2 predicts the prognosis of
glioma patients and functions as a suppressor for gliomas by
suppressing Wnt/β-catenin signaling pathway. Neuropsychiatr Dis
Treat. 13:1805–1813. 2017. View Article : Google Scholar :
|
|
13
|
Liao Y, Shen L, Zhao H, Liu Q, Fu J, Guo
Y, Peng R and Cheng L: lncRNA CASC2 interacts with miR-181a to
modulate glioma growth and resistance to TMZ through PTEN pathway.
J Cell Biochem. 118:1889–1899. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang G, Wu X, Li S, Xu X, Zhu H and Chen
X: The long noncoding RNA CASC2 functions as a competing endogenous
RNA by sponging miR-18a in colorectal cancer. Sci Rep. 6:265242016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang W, He W, Gao J, Wang Y, Zang W, Dong
Z and Zhao G: RETRACTED: The long noncoding RNA CASC2 inhibits
tumorigenesis through modulating the expression of PTEN by
targeting miR-18a-5p in esophageal carcinoma. Exp Cell Res.
361:30–38. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao W, Lin S, Cheng C, Zhu A, Hu Y, Shi Z,
Zhang X and Hong Z: Long non-coding RNA CASC2 regulates Sprouty2
via functioning as a competing endogenous RNA for miR-183 to
modulate the sensitivity of prostate cancer cells to docetaxel.
Arch Biochem Biophys. Jan 23–2018, Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Y, Zhu M, Sun Y, Li W, Wang Y and Yu
W: Up-regulation of lncRNA CASC2 suppresses cell proliferation and
metastasis of breast cancer via inactivating of the TGF-β signaling
pathway. Oncol Res. Mar 9–2018, Epub ahead of print. View Article : Google Scholar
|
|
18
|
Li C, Du X, Tai S, Zhong X, Wang Z, Hu Z,
Zhang L, Kang P, Ji D, Jiang X, et al: GPC1 regulated by miR-96-5p,
rather than miR-182-5p, in inhibition of pancreatic carcinoma cell
proliferation. Int J Mol Sci. 15:6314–6327. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ress AL, Stiegelbauer V, Winter E,
Schwarzenbacher D, Kiesslich T, Lax S, Jahn S, Deutsch A,
Bauernhofer T, Ling H, et al: MiR-96-5p influences cellular growth
and is associated with poor survival in colorectal cancer patients.
Mol Carcinog. 54:1442–1450. 2015. View
Article : Google Scholar
|
|
20
|
Assal RA, El Tayebi HM, Hosny KA, Esmat G
and Abdelaziz AI: A pleiotropic effect of the single clustered
hepatic metastamiRs miR-96-5p and miR-182-5p on insulin-like growth
factor II, insulin-like growth factor-1 receptor and insulin-like
growth factor-binding protein-3 in hepatocellular carcinoma. Mol
Med Rep. 12:645–650. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang K, Wang YW, Wang YY, Song Y, Zhu J,
Si PC and Ma R: Identification of microRNA biomarkers in the blood
of breast cancer patients based on microRNA profiling. Gene.
619:10–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang J, Kong X, Li J, Luo Q, Li X, Shen
L, Chen L and Fang L: miR-96 promotes tumor proliferation and
invasion by targeting RECK in breast cancer. Oncol Rep.
31:1357–1363. 2014. View Article : Google Scholar
|
|
23
|
Hong Y, Liang H, Uzair-Ur-Rehman, Wang Y,
Zhang W, Zhou Y, Chen S, Yu M, Cui S, Liu M, et al: miR-96 promotes
cell proliferation, migration and invasion by targeting PTPN9 in
breast cancer. Sci Rep. 6:374212016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shi Y, Zhao Y, Shao N, Ye R, Lin Y, Zhang
N, Li W, Zhang Y and Wang S: Overexpression of microRNA-96-5p
inhibits autophagy and apoptosis and enhances the proliferation,
migration and invasiveness of human breast cancer cells. Oncol
Lett. 13:4402–4412. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xie W, Sun F, Chen L and Cao X: miR-96
promotes breast cancer metastasis by suppressing MTSS1. Oncol Lett.
15:3464–3471. 2018.PubMed/NCBI
|
|
26
|
Xu YM, Wang HJ, Chen F, Guo WH, Wang YY,
Li HY, Tang JH, Ding Y, Shen YC, Li M, et al: HRD1 suppresses the
growth and metastasis of breast cancer cells by promoting IGF-1R
degradation. Oncotarget. 6:42854–42867. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
28
|
Lo PK, Wolfson B, Zhou X, Duru N,
Gernapudi R and Zhou Q: Noncoding RNAs in breast cancer. Brief
Funct Genomics. 15:200–221. 2016. View Article : Google Scholar :
|
|
29
|
Kondo Y, Shinjo K and Katsushima K: Long
non-coding RNAs as an epigenetic regulator in human cancers. Cancer
Sci. 108:1927–1933. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lu L, Dai Z, Luo Q and Lv G: The long
noncoding RNA cancer susceptibility candidate 2 inhibits tumor
progression in osteosarcoma. Mol Med Rep. 17:1947–1953. 2018.
|
|
31
|
Jiang C, Shen F, Du J, Fang X, Li X, Su J,
Wang X, Huang X and Liu Z: Upregulation of CASC2 sensitized glioma
to temozolomide cytotoxicity through autophagy inhibition by
sponging miR-193a-5p and regulating mTOR expression. Biomed
Pharmacother. 97:844–850. 2018. View Article : Google Scholar
|
